Synapse - Alexander Drilon

Search Within

Alexander Edward Drilon

Results (631)

Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)

Meeting Abstract

Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay

Meeting Abstract

Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping

Journal Article

Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
Cancer Discovery (2015)

Fulltext@MSK | Save

MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking

Journal Article

Arcila, M. E.; Drilon, A.; Sylvester, B. E.; Lovly, C. M.; Borsu, L.; Reva, B.; Kris, M. G.; Solit, D. B.; Ladanyi, M.
Clinical Cancer Research (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay

Meeting Abstract

Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
Modern Pathology (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay

Meeting Abstract

Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
Laboratory Investigation (2015)

Fulltext@MSK | Save

Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas

Meeting Abstract

Eng, J.; Hellmann, M. D.; Woo, K.; Sima, C. S.; Yu, H. A.; Arcila, M. E.; Ladanyi, M.; Kris, M. G.; Drilon, A. E.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers

Meeting Abstract

Drilon, A. E.; Hellmann, M. D.; Wang, L.; Cho, E. J.; Ladanyi, M.; Rizvi, N. A.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in "pan-negative" lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history

Meeting Abstract

Drilon, A. E.; Wang, L.; Arcila, M. E.; Cho, E. J.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

Journal Article

Zauderer, M. G.; Drilon, A.; Kadota, K.; Huberman, K.; Sima, C. S.; Bergagnini, I.; Sumner, D. K.; Travis, W. D.; Heguy, A.; Ginsberg, M. S.; more...
Lung Cancer (2014)

Fulltext@MSK | Save